CD274 and neoplasm: However, analysis of the results of preliminary study related to 45 FDA drug approvals encompassing 15 tumor types and carried out from 2011 to April 2019 indicated that PD-L1 is predictive in only 28.9% of these cases, while the number of cases in which PD-L1 is not predictive is as high as 53.3% [143].